Solvias will provide analytical release testing services for the first genome-edited cell therapy, CASGEVY™, to treat sickle cell disease in patients aged 12 and older. The therapy has gained FDA approval and conditional approval from the EMA for severe sickle cell disease and transfusion-dependent beta thalassemia treatments.
Group-IB’s Threat Intelligence and Defence Centre Equip Undergraduates with Sophisticated Cybersecurity Technologies to Boost Threat Analysis and Enhance Cyber Resilience for Campus Start-ups
Hey there from the heart of the San Francisco Bay Area! It’s an absolute pleasure to have you back again for our chat on some
